Table 2b. Antibody Performance, Weeks 3 to 5 – IgG

IgG	Week 3			Week 4			Week 5		
Sensitivity	0.95 (95% CI: 0.92 to 0.96)			0.88 (95% CI: 0.83 to 0.92)			0.94 (95% CI: 0.88 to 0.97)		
Specificity	0.99 (95% CI: 0.99 to 0.99)								
Outcome	**Effect per 1,000 patients tested**								
	Pre-test Probability								
	1% [a]	**10%** [b]	**40%** [c]	**1%** [a]	**10%** [b]	**40%** [c]	**1%** [a]	**10%** [b]	**40%** [c]
True positives (patients with COVID-19)	10 (9 to 10)	95 (92 to 96)	380 (368 to 384)	9 (8 to 9)	88 (83 to 92)	352 (332 to 368)	9 (9 to 10)	94 (88 to 97)	376 (352 to 388)
False negatives (patients incorrectly classified as not having COVID-19)	0 (0 to 1)	5 (4 to 8)	20 (16 to 32)	1 (1 to 2)	12 (8 to 17)	48 (32 to 68)	1 (0 to 1)	6 (3 to 12)	24 (12 to 48)
Quality of the evidence	16 studies, 2298 patients ⊕⊕⊕◯ MODERATE[d]			8 studies, 840 patients ⊕⊕◯◯ LOW [d,e]			1 study, 139 patients ⊕◯◯◯ VERY LOW[d,e,f]		
	pre-test probability of 1% [a]			**pre-test probability of 10%** [b]			**pre-test probability of 40%** [c]		
True negatives (patients without COVID-19)	980 (980 to 980)			891 (891 to 891)			594 (594 to 594)		
False positives (patients incorrectly classified as having COVID-19)	10 (10 to 10)			9 (9 to 9)			6 (6 to 6)		
Quality of Evidence	25 studies, 11887 patients ⊕⊕⊕◯ MODERATE[d]								

a. Typically seen in general population in areas that are not hotspots
b. Typically seen in general population in high risk populations
c. Typically seen in general population in exposed and nursing homes
d. The case-control design leads to a serious risk of bias
e. Unexplained inconsistency observed with considerably variable sensitivity. Sensitivity Ranges: C3: 0.81-1.0, C4: 0.72-1.0, C5: 0.94
f. Considering the Upper vs Lower limits of the sensitivity's confidence interval would lead to different clinical decisions.